acquir view neutral
year ago earli may acquir synageva hefti premium
compar acquisit recent launch andexxa potenti
seem reason albeit excit debat commerci potenti view
though therapeut overlap two see complementari critic
care busi help drive sale higher assum andexxa sale
view neutral
acquir portola nc repres
premium close price acquisit price also includ net cash
ptla balanc sheet fund transact cash hand
cash long-term debt transact expect
close
driver acquisit note commerci overlap/complementari critic
care busi expect drive andexxa sale higher andexxa use treat
uncontrol bleed peopl take anti-coagul rivaroxaban xarelto
apixaban eliqui first specif revers agent apixaban-
rivaroxaban-tr patient uncontrol bleed andexxa receiv fda
condit approv may full commerci launch januari
eu ondexxya receiv ema condit approv april launch start
august per near complet overlap ahu nmosd
critic care call point andexxa target
andexxa/ondexxya gener sale assum sale reach
factor xa inhibitor standard care patient requir
anti-coagul estim patient us/eu
per accord publish paper tepper et al real-world
comparison bleed risk among non-valvular atrial fibril patient prescrib
apixaban dabigatran rivaroxaban plo one approxim
anticoagulant-tr patient associ major bleed vs per
use rate roughli translat potenti elig patient
us/eu assum roughli
translat us/eu combin market size vs
base run-rate estim modest andexxa/ondexxya sale
vs current consensu estimate
roughli estim dilut prior estim ep
adjust pt vs prior commit expand
pipelin beyond franchis revenu posit remain
seen would help off-set futur impact potenti competitor
develop meaning way
pleas see analyst certif import disclosur inform inform regard statu non-u analyst
page report
estim revenue/ep compound-annual-growth-rate
pt base sum-of-the-part npv
analysi soliris/ultomiri indic includ
pnh ahu gmg
nmo strensiq kanuma
lald wilson diseas
danicopan pnh danicopan
andexxa anticoagul revers account
acquisit price
potenti acquisit pharma
pipelin product
price impact biosimilar and/or new
competitor product lower expect
impact vs impact current estim
see price target
impact soliris/ultomiri
compet trial competit product
plateau soliris/ultomiri sale compet
biosimilar and/or complement inhibitor
pnh/ahus/gmg/nmosd enter market
biosimilar and/or new competitor product
success launch activ price
pressur impact market loss see
fair value-per-share
soliris/ultomiri franchis account
total revenu conveni dose
follow-on product ultomiri make effort
fend potenti futur competit pnh ahu gmg
nmosd howev think may suffici
fulli protect franchis potenti market
entri biosimilar well new chemic entiti
even soliris/ultomiri maintain major market
share activ price pressur competit affect
revenu growth view
pk-base data ultomiri sc
potenti launch pnh/ahu
data danicopan initi
danicopan pnh start
pnh
eu approv ultomiri ahu
data poc studi
initi
time vs hour current
top-lin data wilson diseas
pleas see import disclosur inform page report
data ultomiri sc potenti launch pnh/ahu eu
approv ultomiri ahu portion initi
al amyloidosi vs prior data danicopan
initi danicopan pnh initi
waiha start vs prior initi sc gmg
data poc studi initi indic
select work on-going launch high concentr ultomiri infus time
vs hour current start poc renal basket studi
top-lin data wilson diseas
pleas see import disclosur inform page report
